Highline Capital Management, L.P. Ultragenyx Pharmaceutical Inc. Transaction History

Highline Capital Management, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 14, 2020	SELL	$36.08 - $45.83 $10.7 Million - $13.5 Million	-295,653 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$42.5 - $63.11 $4.03 Million - $5.98 Million	-94,800 Reduced 24.28%	295,653 $12.6 Million
Q2 2019 Aug 14, 2019	SELL	$54.93 - $74.36 $12.1 Million - $16.3 Million	-219,610 Reduced 36.0%	390,453 $24.8 Million
Q1 2019 May 15, 2019	BUY	$39.87 - $69.36 $6.04 Million - $10.5 Million	151,550 Added 33.05%	610,063 $42.3 Million
Q4 2018 Feb 14, 2019	BUY	$38.89 - $77.3 $1.18 Million - $2.35 Million	30,393 Added 7.1%	458,513 $19.9 Million
Q3 2018 Nov 14, 2018	BUY	$71.81 - $90.15 $1.3 Million - $1.63 Million	18,120 Added 4.42%	428,120 $32.7 Million
Q2 2018 Aug 14, 2018	BUY	$48.54 - $85.31 $19.9 Million - $35 Million	410,000 New	410,000 $31.5 Million

325

85.7M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.22B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Highline Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Highline Capital Management, L.P. with notifications on news.